Switch to:
Also traded in: France, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 4700.49
NAS:CLLS's Cash-to-Debt is ranked higher than
58% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:CLLS: 4700.49 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CLLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.8  Med: 94.51 Max: No Debt
Current: 4700.49
Equity-to-Asset 0.83
NAS:CLLS's Equity-to-Asset is ranked higher than
72% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CLLS: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CLLS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.79 Max: 0.83
Current: 0.83
0.77
0.83
Piotroski F-Score: 5
Altman Z-Score: 8.50
Beneish M-Score: -2.82
WACC vs ROIC
12.40%
-1583.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -147.98
NAS:CLLS's Operating Margin % is ranked lower than
55% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:CLLS: -147.98 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CLLS' s Operating Margin % Range Over the Past 10 Years
Min: -494.74  Med: -109.39 Max: -24.25
Current: -147.98
-494.74
-24.25
Net Margin % -125.20
NAS:CLLS's Net Margin % is ranked lower than
54% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:CLLS: -125.20 )
Ranked among companies with meaningful Net Margin % only.
NAS:CLLS' s Net Margin % Range Over the Past 10 Years
Min: -1033.23  Med: -91.42 Max: 1.16
Current: -125.2
-1033.23
1.16
ROE % -19.73
NAS:CLLS's ROE % is ranked higher than
62% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:CLLS: -19.73 )
Ranked among companies with meaningful ROE % only.
NAS:CLLS' s ROE % Range Over the Past 10 Years
Min: -178.26  Med: -19.95 Max: 0.39
Current: -19.73
-178.26
0.39
ROA % -15.88
NAS:CLLS's ROA % is ranked higher than
63% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:CLLS: -15.88 )
Ranked among companies with meaningful ROA % only.
NAS:CLLS' s ROA % Range Over the Past 10 Years
Min: -95.59  Med: -14.91 Max: 0.31
Current: -15.88
-95.59
0.31
ROC (Joel Greenblatt) % -237.08
NAS:CLLS's ROC (Joel Greenblatt) % is ranked higher than
55% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:CLLS: -237.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CLLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -576.68  Med: -401.24 Max: 62.08
Current: -237.08
-576.68
62.08
3-Year Revenue Growth Rate 64.50
NAS:CLLS's 3-Year Revenue Growth Rate is ranked higher than
90% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CLLS: 64.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CLLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 64.5
Current: 64.5
0
64.5
3-Year EBITDA Growth Rate 12.50
NAS:CLLS's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NAS:CLLS: 12.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CLLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.5
Current: 12.5
0
12.5
3-Year EPS without NRI Growth Rate 12.00
NAS:CLLS's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:CLLS: 12.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CLLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12
Current: 12
0
12
GuruFocus has detected 3 Warning Signs with Cellectis SA $NAS:CLLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CLLS's 30-Y Financials

Financials (Next Earnings Date: 2017-09-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:ZIOP, NAS:EPZM, OTCPK:PFSCF, NAS:ASND, NAS:FPRX, NYSE:BHVN, NAS:ACOR, NAS:AMRN, NAS:AKAO, NAS:AMRI, NAS:BYSI, NAS:IMMU, NAS:CHRS, NAS:RVNC, NAS:TGTX, OTCPK:PHMMF, NAS:ADRO, NAS:NDRM, NAS:FWP, NAS:INSY » details
Traded in other countries:ALCLS.France, ZVA.Germany, CMVLF.USA,
Headquarter Location:France
Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants.

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Ratios

vs
industry
vs
history
PB Ratio 3.14
NAS:CLLS's PB Ratio is ranked higher than
62% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:CLLS: 3.14 )
Ranked among companies with meaningful PB Ratio only.
NAS:CLLS' s PB Ratio Range Over the Past 10 Years
Min: 2.11  Med: 3.34 Max: 5.99
Current: 3.14
2.11
5.99
PS Ratio 20.03
NAS:CLLS's PS Ratio is ranked lower than
59% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NAS:CLLS: 20.03 )
Ranked among companies with meaningful PS Ratio only.
NAS:CLLS' s PS Ratio Range Over the Past 10 Years
Min: 9.02  Med: 18.84 Max: 153.76
Current: 20.03
9.02
153.76
EV-to-EBIT -9.50
NAS:CLLS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. NAS:CLLS: -9.50 )
Ranked among companies with meaningful EV-to-EBIT only.
NAS:CLLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -330.2  Med: -18.2 Max: -4.9
Current: -9.5
-330.2
-4.9
EV-to-EBITDA -9.87
NAS:CLLS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. NAS:CLLS: -9.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
NAS:CLLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -363.9  Med: -19.1 Max: -5.1
Current: -9.87
-363.9
-5.1
Current Ratio 5.69
NAS:CLLS's Current Ratio is ranked higher than
61% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:CLLS: 5.69 )
Ranked among companies with meaningful Current Ratio only.
NAS:CLLS' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 3.81 Max: 5.69
Current: 5.69
0.88
5.69
Quick Ratio 5.68
NAS:CLLS's Quick Ratio is ranked higher than
63% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CLLS: 5.68 )
Ranked among companies with meaningful Quick Ratio only.
NAS:CLLS' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.8 Max: 5.68
Current: 5.68
0.87
5.68
Days Inventory 23.08
NAS:CLLS's Days Inventory is ranked higher than
86% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. NAS:CLLS: 23.08 )
Ranked among companies with meaningful Days Inventory only.
NAS:CLLS' s Days Inventory Range Over the Past 10 Years
Min: 21.61  Med: 36.83 Max: 361.63
Current: 23.08
21.61
361.63
Days Sales Outstanding 46.13
NAS:CLLS's Days Sales Outstanding is ranked higher than
66% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:CLLS: 46.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:CLLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.84  Med: 81.45 Max: 529.69
Current: 46.13
24.84
529.69
Days Payable 2.00
NAS:CLLS's Days Payable is ranked lower than
93% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NAS:CLLS: 2.00 )
Ranked among companies with meaningful Days Payable only.
NAS:CLLS' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 1707.16 Max: 2999.57
Current: 2
2
2999.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.80
NAS:CLLS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:CLLS: -18.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:CLLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.7  Med: 0 Max: 0
Current: -18.8
-27.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.84
NAS:CLLS's Price-to-Net-Cash is ranked higher than
76% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. NAS:CLLS: 3.84 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NAS:CLLS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.6  Med: 4.24 Max: 28.03
Current: 3.84
2.6
28.03
Price-to-Net-Current-Asset-Value 3.38
NAS:CLLS's Price-to-Net-Current-Asset-Value is ranked higher than
78% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:CLLS: 3.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:CLLS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.38  Med: 3.84 Max: 22.26
Current: 3.38
2.38
22.26
Price-to-Tangible-Book 3.15
NAS:CLLS's Price-to-Tangible-Book is ranked higher than
69% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:CLLS: 3.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:CLLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.22  Med: 3.64 Max: 25.53
Current: 3.15
2.22
25.53
Price-to-Median-PS-Value 1.06
NAS:CLLS's Price-to-Median-PS-Value is ranked lower than
53% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAS:CLLS: 1.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAS:CLLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.03 Max: 6.52
Current: 1.06
0.68
6.52
Earnings Yield (Greenblatt) % -10.53
NAS:CLLS's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:CLLS: -10.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:CLLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.5  Med: -5.5 Max: -0.3
Current: -10.53
-20.5
-0.3

More Statistics

Revenue (TTM) (Mil) $43.89
EPS (TTM) $ -1.54
Short Percentage of Float0.00%
52-Week Range $16.09 - 28.69
Shares Outstanding (Mil)35.34 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 43 43 43
EPS ($) -0.85 -2.11 -3.01
EPS without NRI ($) -0.85 -2.11 -3.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}